A Phase II Trial of Prostate-Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal of Clinical Oncology - United States
doi 10.1200/jco.2014.32.4_suppl.83
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2014
Authors
Publisher
American Society of Clinical Oncology (ASCO)